Our team
Experienced leaders dedicated to excellence
Curt LaBelle
With a 20 year commitment to advancing healthcare through strategic investments, Curt is the Founder & Chair of Global Health Funds, managing the private investments of the $300M AXA Prime Fund.
Throughout his career, Curt has played pivotal roles on the boards of numerous influential healthcare companies. His board and observer positions have included KAI Pharmaceuticals (acquired by Amgen), Sirion Therapeutics (acquired by Bausch & Lomb and Alcon), Impulse Monitoring (acquired by NuVasive), TransMolecular (acquired by Morphotek), Estech (acquired by AtriCure), Coherex (acquired by Johnson & Johnson), Exagen Diagnostics, SafeOp, and several others.
Previously, Curt served as the managing partner of the $108M Global Health Investment Fund, held the position of managing director at Tullis Health Investors and served as a vice president at Investor Growth Capital.
Mark Sullivan
With over 30 years of pharmaceutical development experience at renowned organisations such as GSK in London and Gilead Sciences in San Francisco, Mark has significantly contributed to the field of global health. In 2005, he founded Medicines Development for Global Health, and in 2020, he established Atticus Medical.
Throughout his career, Mark has worked on over 40 drug development programs, successfully taking four drugs to FDA approval. Notably, he led the FDA regulatory approval for moxidectin, marking the first new treatment for river blindness in more than 20 years.
In recognition of his contributions, Mark was honoured as VIC Australian of the Year in 2019 and an Officer of the Order of Australia in 2023. He serves as an Adjunct Professor at the Kirby Institute, UNSW, and advises both Adjuvant Capital in New York and the AXA Prime Fund in London.
Glenn Rockman
Glenn is a seasoned finance professional with over 20 years of experience in venture capital and investment banking. He is the Managing Partner at Adjuvant Capital, a life sciences investment firm dedicated to global public health. In this role, Glenn oversees the firm's investment practice and its operations.
Before founding Adjuvant Capital in 2018, Glenn co-led the investment team at the Gates Foundation-sponsored Global Health Investment Fund (GHIF). This pioneering venture fund in the life sciences sector was backed by multi-national pharmaceutical companies, development finance institutions, family offices, and foundations.
Previously, Glenn served as an Executive Director in J.P. Morgan’s Social Finance unit, where he helped non-profit clients maximize their financial resources to advance their missions.
Glenn holds an AB in public policy from the Princeton School of Public and International Affairs.
John Lambert
John began his career as an organic chemist, studying at the University of Melbourne, ANU, and Harvard University before spending about seven years in academic research and teaching at The University of Melbourne. With now over 20 years of experience in pharmaceutical development, he has held various leadership roles throughout his career.
John has served as a leader at Biota Pharmaceuticals and as CEO of the ASX-listed Amplia Therapeutics. He also held a significant position as a Senior Director at Medicines Development for Global Health, where he was part of the team that achieved FDA approval in 2018 for moxidectin, a new treatment for river blindness.